CPTx is a biotech platform company developing next-generation in vivo cell therapies. Using proprietary immune-quiet DNA payloads, targeted lipid nanoparticles (LNPs), and advanced DNA engineering technologies, CPTx is building a pipeline of differentiated CAR T cell therapies across oncology and autoimmune diseases. The company builds on more than 15 years of pioneering work in programmable DNA nanofabrication under the leadership of Prof. Hendrik Dietz at the Technical University of Munich. CPTx's leadership team is comprised of some of the world's leading biotech and pharmaceutical companies, and the organization is committed to improving global health through groundbreaking science.
